×

Human Calcipressin-2 (RCAN2) ELISA Kit

  • Cat.No.: AE22621HU

  • Reactivity: Human (Homo sapiens)

To Purchase AE22621HU

Size:
48T 96T
Price: Inquire

Reagent Preparation







Results demonstration







Assay Procedure Summary







Certificate



Product Details

Species Reactivity Human (Homo sapiens)
UniProt Q14206
Abbreviation RCAN2
Alternative Names RP11-38F19.1; CSP2; DSCR1L1; MCIP2; RCN2; ZAKI-4; ZAKI4; hRCN2; Calcipressin 2 (Thyroid hormone-responsive protein ZAKI-4) (Down syndrome candidate region 1-like 1) (Myocyte-enriched calcineurin int
Range Request Information
Sensitivity Request Information
Sample Type Serum, Plasma, Other biological fluids
Detection Method Sandwich
Analysis Method Quantitive
Assay Duration 1-4.5h
Sample Volume 1-200 μL
Detection Wavelengt 450 nm

Test principle

This assay employs a two-site sandwich ELISA to quantitate RCAN2 in samples. An antibody specific for RCAN2 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any RCAN2 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for RCAN2 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of RCAN2 bound in the initial step. The color development is stopped and the intensity of the color is measured.
 

Product Overview

Using a differential display of mRNA by PCR, Miyazaki et al. (1996) cloned a cDNA fragment of a thyroid hormone-responsive gene, which they called ZAKI4 (RCAN2), from cultured human skin fibroblasts. Using 5-prime and 3-prime RACE, they isolated a full-length cDNA, which gives rise to 2 mRNA species, both of which encode a protein of 192 amino acids. Sequence analysis of the ZAKI4 protein suggested that the 2 mRNAs arise by alternative polyadenylation. Northern blot analysis revealed the presence of differentially expressed transcripts of 3.4 and 1.4 kb. The larger transcript is expressed in skin fibroblasts and skeletal muscle, whereas the smaller transcript is found in heart, brain, and liver but not in placenta, lung, kidney, or pancreas.
 

Components


Reagents

Quantity

Reagents

Quantity

Assay plate (96 Wells)

1

Instruction manual

1

Standard (lyophilized)

2

Sample Diluent

1 x 20 mL

Biotin-Conjugate (concentrate 100 x)

1 x 120 μL

Biotin-Conjugate Diluent

1 x 20 mL

Streptavidin-HRP  (concentrate 100 x)

1 x 120 μL

Streptavidin-HRP Diluent   

1 x 20 mL

Wash Buffer (concentrate 25 x)

1 x 20 mL

Substrate Solution

1 x 10 mL

Stop Solution

1 x 10 mL

Adhesive Films

4

 

Specificity

This assay has high sensitivity and excellent specificity for detection of Human RCAN2. No significant cross-reactivity or interference between Human RCAN2 and analogues was observed.
 

Recovery

Matrices listed below were spiked with certain level of recombinant Human RCAN2 and the recovery rates were calculated by comparing the measured value to the expected amount of Human RCAN2 in samples.

Sample Type

Number

Recovery range (%)

Average(%)

Serum

10

90-101

96

EDTA plasma

10

89-97

93

Heparin plasma

10

91-99

95

 

Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in forty separate assays to assess inter-assay precision. CV (%) = SD/meanX100 Intra-Assay: CV<8% Inter-Assay: CV<12%
 

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Human RCAN2 and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample Type

1:2

1:4

1:8

1:16

Serum

78-89%

81-99%

92-103%

95-105%

EDTA plasma

91-101%

90-98%

93-101%

91-98%

Heparin plasma

92-103%

93-102%

92-99%

91-101%

 

Stability

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C).
 

Sample collection and storage

Serum: Use a serum separator tube (SST) and allow samples to clot for two hours at room temperature or overnight at 2 - 8°C before centrifugation for 15 minutes at 1000 × g. Remove serum and assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Plasma: Collect plasma using EDTA, or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 × g at 2 - 8°C within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Other biological fluids: Centrifuge samples for 20 minutes at 1000 × g. Remove particulates and assay immediately or store samples in aliquot at -20°C or -80°C. Avoid repeated freeze/thaw cycles.
 

Kits storage instructions

Store at 2-8°C. Please refer to Instruction Manual.
 
  1. Higher Serum RCAN2 Levels Are Associated with Metabolically Unhealthy Individuals, Either with Obesity or Not
    Regulator of calcineurin 2 (RCAN2) has been documented to cause weight gain and related pathology and metabolism abnormalities in animal researches. The aim of the study was to compare serum RCAN2 concentrations in metabolically healthy (MH) and metabolically unhealthy (MUH) individuals.
  2. Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease IF: 5.810
    The promoting effect of the regulator of calcineurin 2 (RCAN2) in hepatic steatosis has been observed in animal studies. However, the association of RCAN2 with non-alcoholic fatty liver disease (NAFLD) in humans remains unclear.